Overview
The actively managed fund is focused on capturing growth and income opportunities predominantly from Europe.
It invests predominantly in European equities, high yield corporate bonds and convertible bonds.
Each asset class weighting is kept at approximately one third.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
Benefits
Equities, high yield corporate bonds and convertible bonds offer a compelling combination of growth and income opportunities with favorable risk/return characteristics.
Diversification across each asset class at approximately one third reduces overall risk.
Managed by a dedicated team of experts who can draw upon UBS SA国际传谋's experienced European investment teams.
Risks
This fund value may fluctuate given its equity exposure and is also impacted by changes in interest rates due to its fixed income holdings. The fund focuses intentionally on European assets, which may entail additional risks and volatility. All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk). This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.This share class (mdist) may make monthly, gross-of-fee distributions. As a consequence, in addition to income, this share class may also distribute capital. This can have negative tax consequences for investors in some jurisdictions. Investors should seek their own tax advice.
Features
| Asset class |
UBS Asset Allocation Funds UBS European Growth and Income Fund |
| Product domicile |
Luxembourg
|
| Portfolio management |
UBS SA国际传谋 (UK) Ltd., London
|
| Fund management |
UBS SA国际传谋 (Europe) S.A., Luxembourg
|
| Custodian bank |
UBS Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
UBS SA国际传谋 (Singapore) Ltd.
|
| Day of inception |
22 August, 2014
|
| Currency of account |
USD
|
| Close of financial year |
30 September
|
| SFDR Classification |
Art.6
|
| Issue / redemption |
daily
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
1.82% p.a.
|
| Management fee |
1.40% p.a.
|
| Total expense ratio (TER) |
1.82% p.a.
|
| Swing pricing |
yes
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
Customized Benchmark
|
| ISIN |
LU1046463011
|
| Bloomberg Ticker |
UEGIPHU LX
|
Performance and Prices
Percentage growth
as of 22 April, 2026
Cumulative
| USD(%) | |
| YTD | |
| 1M | |
| 3M | |
| 6M | |
| 1Y | 17.68 |
| 2Y | |
| 3Y | 36.83 |
| 5Y | 33.48 |
| ø p.a.5Y | 5.95 |
Current data
| Net asset value | 22.04.2026 | USD 113.80 |
| High - last 12 months | 26.02.2026 | USD 115.95 |
| Low - last 12 months | 24.04.2025 | USD 103.42 |
| Last distribution | 20.04.2026 | USD 0.51 |
| Assets of the unit class in mn | 22.04.2026 | USD 15.66 |
| Assets under management | 22.04.2026 | USD 468.02 |
| Indicative equity dividend yield (gross) | 31.03.2026 | 3.15% |
Structures
By the 10 largest equity positions (in %, as of 31 March, 2026)
|
|
|
| ASML HOLDING NV | 0.76 |
| DEUTSCHE TELEKOM AG | 0.66 |
| NOVARTIS AG | 0.65 |
| ASTRAZENECA PLC | 0.63 |
| SHELL PLC | 0.61 |
By the 10 largest positions (in %, as of 31 March, 2026)
|
|
|
| UBS Lux Bond Fund - Convert Europe EUR | 19.25 |
| UBS Lux Key Selection Sicav - European Equity Value Opportunity | 14.60 |
| UBS Lux Bond SICAV - Convert Global EUR | 14.49 |
| UBS Lux Equity SICAV - European Opportunity Unconstrained EUR | 14.12 |
| UBS Lux Equity SICAV - European High Dividend EUR | 5.21 |
| Nidda Healthcare Holding GmbH | 1.10 |
| Teva Pharmaceutical Finance Netherlands II BV | 1.02 |
| Aroundtown Finance Sarl | 0.78 |
| ZF Europe Finance BV | 0.73 |
| Pinnacle Bidco PLC | 0.60 |
Fees
Ongoing costs p.a.
1.82%
Flat fee
1.75%
Management fee p.a.
1.40%
Max sales charge
6.00%
Max. redemption commission
0.00%
Distribution fee
(see info)
Distributions
From
01-Nov-2020
To
01-Nov-2021
|
Date of distribution
|
Pay date
|
Currency
|
Distribution
|
Ex-date
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 15.05.2025 | 20.05.2025 | 128 | USD | 0.48 | 16.06.2025 | 20.06.2025 | 129 | USD | 0.50 | 15.07.2025 | 18.07.2025 | 130 | USD | 0.49 | 18.08.2025 | 21.08.2025 | 131 | USD | 0.50 | 15.09.2025 | 18.09.2025 | 132 | USD | 0.50 | 15.10.2025 | 20.10.2025 | 133 | USD | 0.50 | 17.11.2025 | 20.11.2025 | 134 | USD | 0.51 | 15.12.2025 | 18.12.2025 | 135 | USD | 0.51 | 15.01.2026 | 20.01.2026 | 136 | USD | 0.51 | 13.02.2026 | 18.02.2026 | 137 | USD | 0.52 | 16.03.2026 | 19.03.2026 | 138 | USD | 0.54 | 15.04.2026 | 20.04.2026 | 139 | USD | 0.51 |
Sales Authorisations
Literature
Brochures
Agreement / Prospectus
|
Document type
|
Document Language
|
| Prospectus |
|
Product Highlight Sheet
|
Document type
|
Document Language
|
| Product Highlight Sheet |
|
Annual and semi-annual report (accounting on 30 September)
|
Document type
|
Document Language
|
| Annual report |
|
| Semi-annual report |
|
Please wait for the requested content to load. If there is no response after several minutes, please reload the page or try again later.